A randomized phase II study to determine the efficacy and tolerability of two doses of eribulin plus lapatinib in trastuzumab pre-treated patients with Her2-positive metastatic breast cancer - E-Vita -
© The Author 2016. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissionsoup.com.Background: Lapatinib (L) in combination with capecitabine has been approved for the treatment of HER2+ adva...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
11 October 2016
|
| In: |
Annals of oncology
Year: 2016, Jahrgang: 27 |
| ISSN: | 1569-8041 |
| DOI: | 10.1093/annonc/mdw365.52 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: http://dx.doi.org/10.1093/annonc/mdw365.52 Verlag, kostenfrei, Volltext: https://academic.oup.com/annonc/article/27/suppl_6/273P/2799012 
|
| Verfasserangaben: | J. Bischoff, J. Barinoff, C. Mundhenke, D. Bauerschlag, S.D. Costa, D. Herr, K. Lübe, F. Marmé, N. Maass, G. von Minckwitz, E.-M. Grischke, V. Müller, M. Schmidt, B. Gerber, S. Kümmel, C. Schumacher, P. Krabisch, M. Thill, V. Nekljudova, S. Loibl |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1565213327 | ||
| 003 | DE-627 | ||
| 005 | 20220814020357.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 171109s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/annonc/mdw365.52 |2 doi | |
| 035 | |a (DE-627)1565213327 | ||
| 035 | |a (DE-576)495213322 | ||
| 035 | |a (DE-599)BSZ495213322 | ||
| 035 | |a (OCoLC)1340981763 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Bischoff, Joachim |e VerfasserIn |0 (DE-588)1043621083 |0 (DE-627)770729576 |0 (DE-576)395160359 |4 aut | |
| 245 | 1 | 2 | |a A randomized phase II study to determine the efficacy and tolerability of two doses of eribulin plus lapatinib in trastuzumab pre-treated patients with Her2-positive metastatic breast cancer - E-Vita - |c J. Bischoff, J. Barinoff, C. Mundhenke, D. Bauerschlag, S.D. Costa, D. Herr, K. Lübe, F. Marmé, N. Maass, G. von Minckwitz, E.-M. Grischke, V. Müller, M. Schmidt, B. Gerber, S. Kümmel, C. Schumacher, P. Krabisch, M. Thill, V. Nekljudova, S. Loibl |
| 264 | 1 | |c 11 October 2016 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 09.11.2017 | ||
| 520 | |a © The Author 2016. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissionsoup.com.Background: Lapatinib (L) in combination with capecitabine has been approved for the treatment of HER2+ advanced breast cancer (ABC) progressed after anthracycline-, taxane-, and trastuzumab (T)-containing therapies. The use is limited by overlapping toxicities. Therefore, other combinations of L with less toxic agents are needed. In the E-VITA study two schedules of Eribulin (E) in association with L have been investigated.Methods: E-VITA (NCT01534455) is a randomized phase II study to determine the efficacy and tolerability of two doses of E plus L in T pre-treated pts with HER2+ ABC. Main eligibility criteria were: ABC not suitable for surgery or radiotherapy alone; adjuvant and up to 3 chemotherapy regimen for ABC. Pts were randomized (1:1) to receive E 1.23mg/m2 iv d1,8 q21 (E1.23)... | ||
| 700 | 1 | |a Marmé, Frederik |d 1974- |e VerfasserIn |0 (DE-588)132561972 |0 (DE-627)52394893X |0 (DE-576)299226549 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of oncology |d Amsterdam [u.a.] : Elsevier, 1990 |g 27(2016,Supplement 6) Artikel-Nummer 273P,1 Seite |h Online-Ressource |w (DE-627)320428796 |w (DE-600)2003498-2 |w (DE-576)098134345 |x 1569-8041 |7 nnas |a A randomized phase II study to determine the efficacy and tolerability of two doses of eribulin plus lapatinib in trastuzumab pre-treated patients with Her2-positive metastatic breast cancer - E-Vita - |
| 773 | 1 | 8 | |g volume:27 |g year:2016 |g supplement:Supplement 6 |a A randomized phase II study to determine the efficacy and tolerability of two doses of eribulin plus lapatinib in trastuzumab pre-treated patients with Her2-positive metastatic breast cancer - E-Vita - |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/annonc/mdw365.52 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u https://academic.oup.com/annonc/article/27/suppl_6/273P/2799012 |x Verlag |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20171109 | ||
| 993 | |a Article | ||
| 994 | |a 2016 | ||
| 998 | |g 132561972 |a Marmé, Frederik |m 132561972:Marmé, Frederik |d 910000 |d 910400 |e 910000PM132561972 |e 910400PM132561972 |k 0/910000/ |k 1/910000/910400/ |p 7 | ||
| 999 | |a KXP-PPN1565213327 |e 2986896626 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"type":{"bibl":"article-journal","media":"Online-Ressource"},"title":[{"title_sort":"randomized phase II study to determine the efficacy and tolerability of two doses of eribulin plus lapatinib in trastuzumab pre-treated patients with Her2-positive metastatic breast cancer - E-Vita -","title":"A randomized phase II study to determine the efficacy and tolerability of two doses of eribulin plus lapatinib in trastuzumab pre-treated patients with Her2-positive metastatic breast cancer - E-Vita -"}],"origin":[{"dateIssuedDisp":"11 October 2016","dateIssuedKey":"2016"}],"note":["Gesehen am 09.11.2017"],"person":[{"role":"aut","given":"Joachim","family":"Bischoff","display":"Bischoff, Joachim"},{"role":"aut","given":"Frederik","display":"Marmé, Frederik","family":"Marmé"}],"id":{"doi":["10.1093/annonc/mdw365.52"],"eki":["1565213327"]},"language":["eng"],"name":{"displayForm":["J. Bischoff, J. Barinoff, C. Mundhenke, D. Bauerschlag, S.D. Costa, D. Herr, K. Lübe, F. Marmé, N. Maass, G. von Minckwitz, E.-M. Grischke, V. Müller, M. Schmidt, B. Gerber, S. Kümmel, C. Schumacher, P. Krabisch, M. Thill, V. Nekljudova, S. Loibl"]},"recId":"1565213327","relHost":[{"title":[{"subtitle":"official journal of the European Society for Medical Oncology","title_sort":"Annals of oncology","title":"Annals of oncology"}],"pubHistory":["1.1990 -"],"origin":[{"publisherPlace":"Amsterdam [u.a.] ; Dordrecht [u.a.] ; Oxford","dateIssuedDisp":"1990-","dateIssuedKey":"1990","publisher":"Elsevier ; Kluwer ; Oxford Univ. Press"}],"note":["Gesehen am 12.11.20","Ungezählte Beil.: Supplement"],"disp":"A randomized phase II study to determine the efficacy and tolerability of two doses of eribulin plus lapatinib in trastuzumab pre-treated patients with Her2-positive metastatic breast cancer - E-Vita -Annals of oncology","type":{"media":"Online-Ressource","bibl":"periodical"},"physDesc":[{"extent":"Online-Ressource"}],"recId":"320428796","id":{"eki":["320428796"],"issn":["1569-8041"],"zdb":["2003498-2"]},"corporate":[{"display":"European Society for Medical Oncology","role":"isb"}],"language":["eng"],"part":{"volume":"27","text":"27(2016,Supplement 6) Artikel-Nummer 273P,1 Seite","year":"2016"}}]} | ||
| SRT | |a BISCHOFFJORANDOMIZED1120 | ||